How tumors escape immune destruction and what we can do about it

被引:122
作者
Gilboa, E [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Surg, Ctr Genet & Cellular Therapies, Durham, NC 27710 USA
关键词
cancer immunotherapy; tumors; immune escape;
D O I
10.1007/s002620050590
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is strong circumstantial evidence that tumor progression in cancer patients is controlled by the immune system. As will be detailed below, this conclusion is based on observations that turner progression is often associated with secretion of immune suppressive factors and/or downregulation of MHC class I antigen presentation functions. The inference is that tumors must have elaborated strategies to circumvent an apparently effective immune response. Importantly, a tumor-specific immune response cannot be detected in most individuals. While this failure is in part technical, it also suggests that the magnitude of the immune responses to which tumors have to respond is low. This raises the concern. which is the underlying theme of this commentary, that a more robust immune response elicited by deliberate vaccination will exacerbate the rate of immune escape and nullify the potential benefits of immune-based therapies.
引用
收藏
页码:382 / 385
页数:4
相关论文
共 31 条
  • [1] Anichini A, 1996, J IMMUNOL, V156, P208
  • [2] BETA(2)-MICROGLOBULIN GENE-MUTATIONS - A STUDY OF ESTABLISHED COLORECTAL CELL-LINES AND FRESH TUMORS
    BICKNELL, DC
    ROWAN, A
    BODMER, WF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) : 4751 - 4755
  • [3] Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
    Boczkowski, D
    Nair, SK
    Snyder, D
    Gilboa, E
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) : 465 - 472
  • [4] BODMER S, 1989, J IMMUNOL, V143, P3222
  • [5] Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo?
    Borrow, P
    Shaw, GM
    [J]. IMMUNOLOGICAL REVIEWS, 1998, 164 : 37 - 51
  • [6] Chen HL, 1996, INT J CANCER, V67, P756, DOI 10.1002/(SICI)1097-0215(19960917)67:6<756::AID-IJC2>3.0.CO
  • [7] 2-Q
  • [8] Cormier JN, 1998, INT J CANCER, V75, P517, DOI 10.1002/(SICI)1097-0215(19980209)75:4<517::AID-IJC5>3.0.CO
  • [9] 2-W
  • [10] ANTIGENIC HETEROGENEITY OF A HUMAN-MELANOMA TUMOR-DETECTED BY AUTOLOGOUS CTL CLONES
    DEGIOVANNI, G
    LAHAYE, T
    HERIN, M
    HAINAUT, P
    BOON, T
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (05) : 671 - 676